Poland· PL-100428692
Maymetsi
A metformin and sitagliptin product containing sitagliptinum + metformini hydrochloridum, registered in Poland by Krka, d.d., Novo mesto. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Metformin and sitagliptin is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BD07 (metformin and sitagliptin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Metformin and sitagliptin · ATC A10BD07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Sitagliptinum + Metformini hydrochloridum
- Manufacturer
- Krka, d.d., Novo mesto
- Country
- Poland (PL)
- ATC code
- A10BD07
- ATC class
- Metformin and sitagliptin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
1 priced- gtin0383898974455756 szt.PLN 38.72
- gtin03838989730093
- gtin03838989730109
- gtin03838989744540
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and sitagliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and sitagliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under A10BD07
Metformin and sitagliptin, as other registers publish it.
- ItalyADIABINPHARMEXTRACTA S.P.A.
- ItalyADIABINPHARMEXTRACTA S.P.A.
- PolandAnsifora DuoVipharm S.A.
- CzechiaANSIFORA DUOVipharm S.A., Ożarów Mazowiecki
- CzechiaANSIFORA DUOVipharm S.A., Ożarów Mazowiecki
- CzechiaANSIFORA DUOVipharm S.A., Ożarów Mazowiecki
- CzechiaANSIFORA DUOVipharm S.A., Ożarów Mazowiecki
- CzechiaANSIFORA DUOVipharm S.A., Ożarów Mazowiecki
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fc5141bf-9995-4d7b-bfc5-e9893063a1af GET /v1/drugs/fc5141bf-9995-4d7b-bfc5-e9893063a1af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg + 1000 mg",
"packaging": "03838989730093 ¦ Rp ¦ 140032\n28 tabl.\n03838989730109 ¦ Rp ¦ 140033\n56 tabl.\n03838989744540 ¦ Rp ¦ 146143\n28 tabl.\n03838989744557 ¦ Rp ¦ 146144\n56 tabl.",
"substance": "Sitagliptinum 50 mg + Metformini hydrochloridum 1000 mg",
"common_name": "Sitagliptinum + Metformini hydrochloridum",
"pl_product_id": "100428692",
"pozwolenie_nr": "26367",
"auth_procedure": "DCP",
"authorisation_validity": "2026-04-22"
}See everything about metformin and sitagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.